Leukemia drug dosing showdown: one shot or two?
NCT ID NCT02716233
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 34 times
Summary
This study looks at how to best give a chemotherapy drug called pegaspargase to children and teenagers with acute lymphoblastic leukemia (ALL). About 2,000 participants will either get one large dose or two smaller doses of the drug during treatment. The goal is to see which method works better and causes fewer side effects, helping improve cure rates for this blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU
Besançon, 25030, France
-
CHU
Amiens, 80054, France
-
CHU
Angers, 49033, France
-
CHU
Bordeaux, 33076, France
-
CHU
Brest, 29609, France
-
CHU
Caen, 14033, France
-
CHU
Clermont-Ferrand, 63003, France
-
CHU
Dijon, 21079, France
-
CHU
Grenoble, 38043, France
-
CHU
Lille, 59037, France
-
CHU
Limoges, 87042, France
-
CHU
Marseille, 13385, France
-
CHU
Montpellier, 34295, France
-
CHU
Nancy, 54511, France
-
CHU
Nantes, 44093, France
-
CHU
Nice, 06200, France
-
CHU
Poitiers, 86000, France
-
CHU
Reims, 51100, France
-
CHU
Rennes, 35203, France
-
CHU
Rouen, 76031, France
-
CHU
Saint-Etienne, 42270, France
-
CHU
Strasbourg, 67098, France
-
CHU
Toulouse, 31059, France
-
CHU
Tours, 37044, France
-
CHU Armand Trousseau
Paris, 75012, France
-
CHU Robert Debré
Paris, 75019, France
-
CHU Saint Louis
Paris, 75010, France
-
Chu-Ihope
Lyon, 69373, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.